Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.

The on-demand webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CTP-543 in adults with alopecia areata, a serious autoimmune dermatological condition. The Company is also evaluating the use of CTP-543 in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005117/en/

Justine Koenigsberg
(781) 674-5284
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• Corning Announces Quarterly Dividend
• Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
• Time for Doug Ford to face reality: CUPE Ontario